135 completed, 36 terminated, 22 unknown, 13 withdrawn. 233 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 233 | Completed 135, Terminated 36, Unknown 22, Withdrawn 13, Active not recruiting 12, Recruiting 10, Not yet recruiting 3, Enrolling by invitation 2 |
Follow Demyelinating Diseases: new trials by email Literature Review of Demyelinating Diseases trials Research Report on Demyelinating Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Jay C. Buckey Jr. | 100 | 2026-11-01 | 2026-09-09 |
| Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial Two-dose M0-M2 vaccination schedule, Two-dose M0-M6 vaccination schedule - Vaccine, Varicella-zoster Virus | Phase 4 | Not yet recruiting | University Hospital, Toulouse | 160 | 2026-10-20 | 2026-09-14 |
| A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy OCR SC - Multiple Sclerosis | Phase 4 | Recruiting | Genentech, Inc. | 100 | 2026-09-02 | 2026-10-30 |
| Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial Crisugabalin, Placebo+Crisugabalin - Neuromyelitis Optica Spectrum Disorders (NMOSD), Neuropathic Pain | Phase 4 | Not yet recruiting | Tang-Du Hospital | 110 | 2026-06-15 | 2026-07-13 |
| Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector - Multiple Sclerosis, Erectile Dysfunction | Phase 4 | Withdrawn | Tulane University | 2026-06-01 | 2026-10-02 | |
| Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis Silodosin 8 mg, Placebo - Multiple Sclerosis, Lower Urinary Track Symptoms | Phase 4 | Recruiting | Atlantic Health System | 60 | 2026-04-01 | 2026-05-29 |
| Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis Ublituximab, Ocrelizumab - Multiple Sclerosis | Phase 4 | Recruiting | Johns Hopkins University | 50 | 2026-02-10 | 2026-05-06 |
| Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study Eculizumab+IVMP, IVIG+IVMP, IVMP - Neuromyelitis Optica Spectrum Disorder Attack | Phase 4 | Recruiting | Chinese PLA General Hospital | 200 | 2026-02-01 | 2026-03-12 |
| Individualised Cryoneurolysis to Treat Pain in the Context of Spasticity in the Upper and Lower Extremities Cryoneurolysis, Botulinum toxin - Centreal Neurological Condition, Acquired Brain Injury (Including Stroke) | Phase 4 | Recruiting | Oxford University Hospitals NHS Trust | 50 | 2025-12-02 | 2026-11-05 |
| Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis Ublituximab - Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting | Phase 4 | Recruiting | Northwestern University | 40 | 2025-11-28 | 2026-03-17 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis Ocrelizumab - Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis | Phase 4 | Active not recruiting | Hoffmann-La Roche | 60 | 2025-07-04 | 2026-09-30 |
| Glucose Consumption in MS Using [F-18]FDG-PET [F-18]FDG - Multiple Sclerosis | Phase 4 | Recruiting | Brigham and Women's Hospital | 50 | 2025-05-31 | 2026-01-09 |
| Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis Ocrelizumab - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Enrolling by invitation | University of California, San Francisco | 5 | 2025-02-04 | 2026-03-27 |
| A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC Efgartigimod PH20 SC - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 4 | Completed | argenx | 23 | 2024-12-10 | 2026-04-06 |
| ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS ETNATM-ProgMS - Relapsing Remitting Multiple Sclerosis (RRMS) | Phase 4 | Recruiting | Novartis Pharmaceuticals | 224 | 2024-11-27 | 2026-05-15 |
| Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis Ofatunumab - Multiple Sclerosis | Phase 4 | Active not recruiting | Novartis Pharmaceuticals | 24 | 2024-11-25 | 2026-08-12 |
| Upper Limb Robot-Assisted Therapy in Patients With Guillain-Barré Syndrome Armeo® Power 2 Exoskeleton - Active Rehabilitation with Feedback and Exercise Gaming, Armeo® Power 2 Exoskeleton - Passive Mobilization without Feedback - Guillain Barré Syndrome | Phase 4 | Active not recruiting | I.R.C.C.S. Fondazione Santa Lucia | 62 | 2024-10-01 | 2026-09-18 |
| Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MS Ozanimod - Multiple Sclerosis | Phase 4 | Withdrawn | The University of Texas at Dallas | 2024-06-01 | 2024-08-09 | |
| Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) Blood tests, Inebilizumab - Neuromyelitis Optica Spectrum Disorder | Phase 4 | Active not recruiting | Amgen | 32 | 2024-04-02 | 2025-11-21 |
| A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders Inebilizumab - Neuromyelitis Optica Spectrum Disorders | Phase 4 | Unknown | Hansoh BioMedical R&D Company | 33 | 2024-02-25 | 2024-01-18 |
Showing 20 of 233. Sign in to see all of them.
Multiple Sclerosis (166) · Multiple Sclerosis, Relapsing-Remitting (81) · Neuromyelitis Optica (10) · Recurrence (6) · Fatigue (5) · Multiple Sclerosis, Chronic Progressive (5) · Muscle Spasticity (4) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (4) · Neuralgia (3) · Optic Neuritis (3) · Stroke (3) · COVID-19 (2) · Cognitive Dysfunction (2) · Depression (2)
Nervous System Diseases (233) · Immune System Diseases (232) · Autoimmune Diseases (231) · Autoimmune Diseases of the Nervous System (230) · Demyelinating Autoimmune Diseases, CNS (225) · Multiple Sclerosis (50) · Pathological Conditions, Signs and Symptoms (41) · Signs and Symptoms (23) · Pathologic Processes (20) · Disease Attributes (16) · Cranial Nerve Diseases (15) · Eye Diseases (15) · Neurologic Manifestations (14) · Optic Nerve Diseases (14)
Interferon beta-1a (30) · Fingolimod Hydrochloride (23) · Dimethyl Fumarate (17) · Natalizumab (16) · Glatiramer Acetate (15) · ocrelizumab (15) · Interferon beta-1b (11) · Methylprednisolone (11) · Cladribine (8) · 4-Aminopyridine (6) · Adrenocorticotropic Hormone (5) · Alemtuzumab (5) · peginterferon beta-1a (5) · teriflunomide (5) · Cholecalciferol (4)
Biogen (33) · Novartis Pharmaceuticals (28) · Merck KGaA, Darmstadt, Germany (7) · Hoffmann-La Roche (6) · Bayer (5) · EMD Serono (5) · Tehran University of Medical Sciences (5) · Teva Branded Pharmaceutical Products R&D, Inc. (5) · Amsterdam UMC, location VUmc (3) · Brown, Theodore R., M.D., MPH (3) · Claudio Gobbi (3) · Genzyme, a Sanofi Company (3) · Johns Hopkins University (3) · Multiple Sclerosis Center of Northeastern New York (3) · Sanofi (3)
United States (94) · Germany (34) · France (30) · Italy (25) · Spain (21) · United Kingdom (20) · Canada (16) · Belgium (15) · Czechia (14) · Netherlands (14) · Switzerland (14) · Denmark (13) · Poland (13) · Sweden (13) · Austria (11)
MerriKay Oleen-Burkey, Ph.D. (3) · Theodore R Brown, MD, MPH (3) · Andrew D Goodman, MD (2) · Bianca Weinstock-Guttman, MD (2) · Claudio Gobbi, MD (2) · Cristina Ramo, MD (2) · Henrik B Jensen, MD (2)
PMID 12525714, PMID 40756532, PMID 40970353, PMID 41943490, PMID 10077661, PMID 10641699, PMID 10695888, PMID 10811692, PMID 12167681, PMID 14606742, PMID 15147583, PMID 15304586, PMID 16283615, PMID 16638802, PMID 16831964, PMID 16980142, PMID 17588298, PMID 17895294, PMID 17942508, PMID 18071030, PMID 18653737, PMID 18789766, PMID 18951800, PMID 19068404, PMID 19073949, PMID 19279320, PMID 19687024, PMID 19752302, PMID 1992392, PMID 20028712, PMID 2023770, PMID 20542736, PMID 20594850, PMID 20976768, PMID 21111490, PMID 21112438, PMID 21400196, PMID 21742556, PMID 22315143, PMID 22354743, PMID 22362918, PMID 2252363, PMID 2297305, PMID 23247892, PMID 23535489, PMID 23767916, PMID 23791482, PMID 23868508, PMID 23915113, PMID 23962697
2015 (5), 2014 (4), 2017 (4), 2016 (2), 2018 (2), 2005 (1), 2019 (1), 2023 (1), 2025 (1), U01AI195194 (1)